NCT07001397View on ClinicalTrials.gov

Study on the Short-term Efficacy and Safety of Recombinant Human Thrombopoietin Combined With Immunosuppressant Sequential Eltrombopag Ethanolamine Dry Suspension in the Treatment of SAA/TD-NSAA

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 23, 2025

Primary Completion Date

March 23, 2026

Study Completion Date

March 23, 2027

Conditions
Aplastic Anemias
Interventions
DRUG

EPAG-pfos

The initial dose of EPAG-pfos is 150mg/d orally. The dose is adjusted according to hematological indicators, with a maximum dose of 150mg/d until hematological remission is achieved

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER